Menu Search
Equities

Twist Bioscience Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0ME:STU

Twist Bioscience Corp

Actions
  • Price (EUR)41.02
  • Today's Change1.29 / 3.25%
  • Shares traded0.00
  • 1 Year change-8.84%
  • Beta2.2480
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.

  • Revenue in USD (TTM)391.56m
  • Net income in USD-76.58m
  • Incorporated2013
  • Employees979.00
  • Location
    Twist Bioscience Corp681 Gateway Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (800) 719-0671
  • Fax+1 (302) 531-3150
  • Websitehttps://www.twistbioscience.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.